Superiority of letrozole over tamoxifen in the first-line treatment of metastatic breast cancer patients with normal serum HER-2/neu levels:: question of tamoxifen resistance -: In Reply

被引：0
|
作者：
Lipton, A [1 ]
Leitzel, K
Demers, L
Harvey, HA
Ali, SM
Chaudri-Ross, HA
Wyld, P
Brady, C
Carney, W
机构：
[1] MS Hershey Med Ctr, Hershey, PA USA
[2] Vet Adm Med Ctr, Lebanon, PA USA
[3] Novartis Pharma AG, Basel, Switzerland
[4] Novartis Pharmaceut Corp, E Hanover, NJ USA
[5] Bayer Corp, Tarrytown, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2003年 / 21卷 / 24期
关键词：
D O I：
10.1200/JCO.2003.99.187
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4657 / 4657
页数：1
相关论文
共 50 条
  • [21] A Stochastic Economic Evaluation of Letrozole versus Tamoxifen as a First-Line Hormonal TherapyFor Advanced Breast Cancer in Postmenopausal Patients
    Jon Karnon
    Trefor Jones
    PharmacoEconomics, 2003, 21 : 513 - 525
  • [22] Monitoring serum HER-2/neu levels in metastatic breast cancer patients undergoing Herceptin® therapy regimens.
    Brown-Shimer, SL
    Schwartz, MK
    Schwartz, D
    Lin, D
    Carney, WP
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S111 - S111
  • [23] A Stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy - For advanced breast cancer in postmenopausal patients
    Karnon, J
    Jones, T
    PHARMACOECONOMICS, 2003, 21 (07) : 513 - 525
  • [24] Correlation of serum HER-2/neu extracellular domain levels in metastatic breast cancer with the expression of HER-2/neu determined by immunohistochemistry in primary tumors.
    Witzel, I
    Thomssen, C
    Pantel, K
    Neumann, R
    Carney, W
    Loening, T
    Jaenicke, F
    Mueller, V
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S143 - S143
  • [25] Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer
    Ali, SM
    Leitzel, K
    Chinchilli, VM
    Engle, L
    Demers, L
    Harvey, HA
    Carney, W
    Allard, JW
    Lipton, A
    CLINICAL CHEMISTRY, 2002, 48 (08) : 1314 - 1320
  • [26] Targeted molecular characterization of serum derived cell free DNA from metastatic breast cancer patients treated with first-line tamoxifen
    Jansen, Maurice
    Beaufort, Corine
    Helmijr, Jean
    van Marion, Ronald
    Krol, Niels
    Monkhorst, Kim
    van Fessem, Marian
    van Schaik, Ron
    Smid, Marcel
    van Gelder, Marion Meijer
    Look, Maxime
    Trapman, Anita
    Ramirez-Ardila, Diana
    Lurkin, Irene
    Zwarthoff, Ellen
    Martens, John
    Foekens, John
    Dinjens, Winand
    Sleijfer, Stefan
    Berns, Els
    CANCER RESEARCH, 2015, 75
  • [27] Clinical utility of determination of HER-2/neu and EGFR fragments in serum of patients with metastatic breast cancer
    Witzel, I.
    Thomssen, C.
    Krenkel, S.
    Wilczak, W.
    Bubenheim, A.
    Pantel, K.
    Neumann, R.
    Jaenicke, F.
    Mueller, V.
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2006, 21 (03): : 131 - 140
  • [28] The correlation of serum HER-2/neu and CA15-3 in patients with metastatic breast cancer
    Park, Nae-Kyeong
    Woo, Hee-Doo
    Sohn, Doo-Min
    Kim, Sung-Yong
    Lim, Cheol-Wan
    Choi, Tae-Youn
    Kim, Jae-Jun
    Lee, Min-Hyuk
    JOURNAL OF BREAST CANCER, 2008, 11 (01) : 18 - 24
  • [29] A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy for advanced breast cancer in postmenopausal patients in Germany
    Fricke, FU
    Quednau, K
    Pirk, O
    VALUE IN HEALTH, 2002, 5 (06) : 443 - 443
  • [30] Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer
    Mansour, Maged
    Mourad, Cynthia
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (02) : 429 - 435
12345